U.S. patent application number 10/193600 was filed with the patent office on 2003-05-01 for carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain.
Invention is credited to Codd, Ellen C., Plata-Salaman, Carlos R., Zhao, Boyu.
Application Number | 20030083372 10/193600 |
Document ID | / |
Family ID | 26889161 |
Filed Date | 2003-05-01 |
United States Patent
Application |
20030083372 |
Kind Code |
A1 |
Codd, Ellen C. ; et
al. |
May 1, 2003 |
Carbamate compounds for use in preventing or treating neuropathic
pain and cluster and migraine headache-associated pain
Abstract
This invention is directed to a method for preventing or
treating neuropathic pain and cluster and migraine
headache-associated pain comprising administering to a subject in
need thereof a therapeutically effective amount of a compound of
Formula (I): 1 wherein phenyl is substituted at X with one to five
halogen atoms independently selected from the group consisting of
fluorine, chlorine, bromine and iodine; and; R.sub.1, R.sub.2,
R.sub.3 and R.sub.4 are independently selected from the group
consisting of hydrogen and C.sub.1-C.sub.4 alkyl; wherein
C.sub.1-C.sub.4 alkyl is optionally substituted with phenyl
(wherein phenyl is optionally substituted with substituents
independently selected from the group consisting of hydrogen,
halogen, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, amino,
nitro and cyano).
Inventors: |
Codd, Ellen C.; (Blue Bell,
PA) ; Plata-Salaman, Carlos R.; (Ambler, PA) ;
Zhao, Boyu; (Lansdale, PA) |
Correspondence
Address: |
AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
26889161 |
Appl. No.: |
10/193600 |
Filed: |
July 11, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60305636 |
Jul 16, 2001 |
|
|
|
Current U.S.
Class: |
514/483 |
Current CPC
Class: |
A61K 31/27 20130101;
A61P 25/02 20180101; A61P 25/04 20180101; A61P 25/06 20180101 |
Class at
Publication: |
514/483 |
International
Class: |
A61K 031/325 |
Claims
What is claimed is:
1. A method for preventing or treating neuropathic pain and cluster
and migraine headache-associated pain comprising administering to a
subject in need thereof a therapeutically effective amount of a
compound of Formula (I): 12wherein phenyl is substituted at X with
one to five halogen atoms independently selected from the group
consisting of fluorine, chlorine, bromine and iodine; and, R.sub.1,
R.sub.2, R.sub.3 and R.sub.4 are independently selected from the
group consisting of hydrogen and C.sub.1-C.sub.4 alkyl; wherein
C.sub.1-C.sub.4 alkyl is optionally substituted with phenyl
(wherein phenyl is optionally substituted with substituents
independently selected from the group consisting of halogen,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, amino, nitro and
cyano).
2. A method for preventing or treating neuropathic pain comprising
administering to a subject in need thereof a therapeutically
effective amount of a compound of Formula (I): 13wherein phenyl is
substituted at X with one to five halogen atoms independently
selected from the group consisting of fluorine, chlorine, bromine
and iodine; and, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are
independently selected from the group consisting of hydrogen and
C.sub.1-C.sub.4 alkyl; wherein C.sub.1-C.sub.4 alkyl is optionally
substituted with phenyl (wherein phenyl is optionally substituted
with substituents independently selected from the group consisting
of halogen, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, amino,
nitro and cyano).
3. A method for preventing or treating cluster and migraine
headache-associated pain comprising administering to a subject in
need thereof a therapeutically effective amount of a compound of
Formula (I): 14wherein phenyl is substituted at X with one to five
halogen atoms independently selected from the group consisting of
fluorine, chlorine, bromine and iodine; and, R.sub.1, R.sub.2,
R.sub.3 and R.sub.4 are independently selected from the group
consisting of hydrogen and C.sub.1-C.sub.4 alkyl; wherein
C.sub.1-C.sub.4 alkyl is optionally substituted with phenyl
(wherein phenyl is optionally substituted with substituents
independently selected from the group consisting of halogen,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, amino, nitro and
cyano).
4. The method of claim 1 wherein X is chlorine.
5. The method of claim 1 wherein X is substituted at the ortho
position of the phenyl ring.
6. The method of claim 1 wherein R.sub.1, R.sub.2, R.sub.3 and
R.sub.4 are selected from hydrogen.
7. The method of claim 1 wherein the compound of Formula (I) is
selected from the group consisting of a racemic mixture of a
compound of Formula (I), an enantiomer of a compound of Formula (I)
and an enantiomeric mixture wherein an enantiomer of a compound of
Formula (I) predominates.
8. The method of claim 7 wherein an enantiomer of Formula (I)
predominates to the extent of about 90% or greater.
9. The method of claim 7 wherein an enantiomer of Formula (I)
predominates to the extent of about 98% or greater.
10. The method of claim 1 wherein the compound of Formula (I) is a
compound of Formula (Ia): 15wherein R.sub.1, R.sub.2, R.sub.3 and
R.sub.4 are independently selected from the group consisting of
hydrogen and C.sub.1-C.sub.4 alkyl; wherein C.sub.1-C.sub.4 alkyl
is optionally substituted with phenyl (wherein phenyl is optionally
substituted with substituents independently selected from the group
consisting of halogen, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
alkoxy, amino, nitro and cyano).
11. The method of claim 10 wherein R.sub.1, R.sub.2, R.sub.3 and
R.sub.4 are selected from hydrogen.
12. The method of claim 10 wherein the compound of Formula (Ia) is
selected from the group consisting of a racemic mixture of a
compound of Formula (Ia), an enantiomer of a compound of Formula
(Ia) and an enantiomeric mixture wherein an enantiomer of a
compound of Formula (Ia) predominates.
13. The method of claim 12 wherein an enantiomer of Formula (Ia)
predominates to the extent of about 90% or greater.
14. The method of claim 12 wherein an enantiomer of Formula (Ia)
predominates to the extent of about 98% or greater.
15. The method of claim 1 wherein the compound of Formula (I) is a
compound of Formula (Ib): 16
16. The method of claim 15 wherein the compound of Formula (Ib) is
selected from the group consisting of a racemic mixture of the
compound of Formula (Ib), an enantiomer of the compound of Formula
(Ib) and an enantiomeric mixture wherein an enantiomer of the
compound of Formula (Ib) predominates.
17. The method of claim 16 wherein an enantiomer of Formula (Ib)
predominates to the extent of about 90% or greater.
18. The method of claim 16 wherein an enantiomer of Formula (Ib)
predominates to the extent of about 98% or greater.
19. The method of claim 1 wherein the compound of Formula (I) is an
enantiomer of Formula (Ic) or an enantiomeric mixture wherein the
enantiomer of Formula (Ic) predominates: 17Formula (Ic)
20. The method of claim 19 wherein the enantiomer of Formula (Ic)
predominates to the extent of about 90% or greater.
21. The method of claim 19 wherein the enantiomer of Formula (Ic)
predominates to the extent of about 98% or greater.
22. The method of claim 2 wherein the compound of Formula (I) is a
compound of Formula (Ib): 18
23. The method of claim 22 wherein the compound of Formula (Ib) is
selected from the group consisting of a racemic mixture of the
compound of Formula (Ib), an enantiomer of the compound of Formula
(Ib) and an enantiomeric mixture wherein an enantiomer of the
compound of Formula (Ib) predominates.
24. The method of claim 23 wherein an enantiomer of Formula (Ib)
predominates to the extent of about 90% or greater.
25. The method of claim 23 wherein an enantiomer of Formula (Ib)
predominates to the extent of about 98% or greater.
26. The method of claim 2 wherein the compound of Formula (I) is an
enantiomer of Formula (Ic) or an enantiomeric mixture wherein the
enantiomer of Formula (Ic) predominates: 19
27. The method of claim 26 wherein the enantiomer of Formula (Ic)
predominates to the extent of about 90% or greater.
28. The method of claim 26 wherein the enantiomer of Formula (Ic)
predominates to the extent of about 98% or greater.
29. The method of claim 2 wherein neuropathic pain results from
chronic or debilitating conditions.
30. The method of claim 29 wherein the chronic or debilitating
conditions are selected from the group consisting of painful
diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal
neuralgia, post-stroke pain, multiple sclerosis-associated pain,
neuropathies-associated pain such as in idiopathic or
post-traumatic neuropathy and mononeuritis, HIV-associated
neuropathic pain, cancer-associated neuropathic pain, carpal
tunnel-associated neuropathic pain, spinal cord injury-associated
pain, complex regional pain syndrome, fibromyalgia-associated
neuropathic pain, lumbar and cervical pain, reflex sympathic
dystrophy, phantom limb syndrome and other chronic and debilitating
condition-associated pain syndromes.
31. The method of claim 26 wherein the therapeutically effective
amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.
32. The method of claim 3 wherein the compound of Formula (I) is a
compound of Formula (Ib): 20
33. The method of claim 32 wherein the compound of Formula (Ib) is
selected from the group consisting of a racemic mixture of the
compound of Formula (Ib), an enantiomer of the compound of Formula
(Ib) and an enantiomeric mixture wherein an enantiomer of the
compound of Formula (Ib) predominates.
34. The method of claim 33 wherein an enantiomer of Formula (Ib)
predominates to the extent of about 90% or greater.
35. The method of claim 33 wherein an enantiomer of Formula (Ib)
predominates to the extent of about 98% or greater.
36. The method of claim 3 wherein the compound of Formula (I) is an
enantiomer of Formula (Ic) or an enantiomeric mixture wherein the
enantiomer of Formula (Ic) predominates: 21
37. The method of claim 36 wherein the enantiomer of Formula (Ic)
predominates to the extent of about 90% or greater.
38. The method of claim 36 wherein the enantiomer of Formula (Ic)
predominates to the extent of about 98% or greater.
39. The method of claim 1 wherein the method is a method for
slowing or delaying the progression of neuropathic pain and cluster
and migraine headache-associated pain comprising administering to a
subject in need thereof a therapeutically effective amount of a
compound of Formula (I).
40. The method of claim 39 wherein the therapeutically effective
amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority from U.S. provisional
application Serial No. 60/305,636 filed Jul. 16, 2001, the contents
of which are hereby incorporated by reference.
FIELD OF THE INVENTION
[0002] This invention is directed to a method for use of a
carbamate compound in preventing or treating neuropathic pain and
cluster and migraine headache-associated pain. More particularly,
this invention is directed to a method for use of a halogenated
2-phenyl-1,2-ethanediol dicarbamate compound for preventing or
treating neuropathic pain and cluster and migraine
headache-associated pain.
BACKGROUND OF THE INVENTION
[0003] The conditions grouped under the term neuropathic pain
constitute an area of continuing medical need.
[0004] Neuropathic pain is defined as pain caused by aberrant
somatosensory processing in the peripheral or central nervous
system and includes painful diabetic peripheral neuropathy,
post-herpetic neuralgia, trigeminal neuralgia, post-stroke pain,
multiple sclerosis-associated pain, neuropathies-associated pain
such as in idiopathic or post-traumatic neuropathy and
mononeuritis, HIV-associated neuropathic pain, cancer-associated
neuropathic pain, carpal tunnel-associated neuropathic pain, spinal
cord injury-associated pain, complex regional pain syndrome,
fibromyalgia-associated neuropathic pain, lumbar and cervical pain,
reflex sympathic dystrophy, phantom limb syndrome and other chronic
and debilitating condition-associated pain syndromes.
[0005] Cluster headache (also called Raeder's syndrome, histamine
cephalalgia and sphenopalatine neuralgia) is characterized by a
series of short-lived attacks of periorbital pain on an almost
daily basis over a relatively short period of time (for example,
over 4 to 8 weeks) followed by a pain-free interval. Migraine
headache is also a periodic recurring disorder that can be
associated with paroxysmal pain, vomiting, and photophobia.
Migraine headaches include, and are not limited to, classic
migraine (migraine with aura: associated with premonitory sensory,
motor or visual symptoms) and common migraine (migraine without
aura). Cluster and migraine headache-associated pain are also
clinical indications with significant unmet medical need.
[0006] Neuropathic pain, migraine and cluster headache are all
associated with changes in neuronal excitability (Mulleners W. M.,
et al, Visual Cortex Excitability in Migraine With and Without
Aura, Headache, June 2001, 41(6), 565-572; Aurora S. K., et al, The
occipital cortex is hyperexcitable in migraine: experimental
evidence, Headache, July-August 1999, 39(7), 469-76; Brau M. E., et
al, Effect of drugs used for neuropathic pain management on
tetrodotoxin-resistant Na(+) currents in rat sensory neurons,
Anesthesiology, January 2001, 94(1), 137-44; Siddall P. J. and
Loeser J. D., Pain following spinal cord injury, Spinal Cord,
February 2001, 39(2), 63-73; Kontinen V. K., et al,
Electrophysiologic evidence for increased endogenous gabaergic but
not glycinergic inhibitory tone in the rat spinal nerve ligation
model of neuropathy, Anesthesiology, February 2001, 94(2), 333-9).
Various anti-epileptic drugs (AEDs) that stabilize neuronal
excitability are effective in neuropathic pain and cluster and
migraine headache-associated pain (Delvaux V. and Schoenen J., New
generation anti-epileptics for facial pain and headache, Acta
Neurol. Belg., March 2001, 101 (1), 42-46; Johannessen C. U.,
Mechanisms of action of valproate: a commentatory, Neurochem. Int.,
August-September 2000, 37(2-3), 103-110 and Magnus L., Nonepileptic
uses of gabapentin, Epilepsia, 1999, 40 Suppl 6, S66-72).
Neuropathic pain and cluster and migraine headache-associated pain
are widespread conditions that cause suffering.
[0007] Substituted phenyl alkyl carbamate compounds have been
described in U.S. Pat. No. 3,265,728 to Bossinger, et al (hereby
incorporated by reference), as useful in treating the central
nervous system, having tranquilization, sedation and muscle
relaxation properties of the formula: 2
[0008] wherein R.sub.1 is either carbamate or alkyl carbamate
containing from 1 to 3 carbon atoms in the alkyl group; R.sub.2 is
either hydrogen, hydroxy, alkyl or hydroxy alkyl containing from 1
to 2 carbons; R.sub.3 is either hydrogen or alkyl containing from 1
to 2 carbons; and X can be halogen, methyl, methoxy, phenyl, nitro
or amino.
[0009] A method for inducing calming and muscle relaxation with
carbamates has been described in U.S. Pat. No. 3,313,692 to
Bossinger, et al (hereby incorporated by reference) by
administering a compound of the formula: 3
[0010] in which W represents an aliphatic radical containing less
than 4 carbon atoms, wherein R.sub.1 represents an aromatic
radical, R.sub.2 represents hydrogen or an alkyl radical containing
less than 4 carbon atoms, and X represents hydrogen or hydroxy or
alkoxy and alkyl radicals containing less than 4 carbon atoms or
the radical: 4
[0011] in which B represents an organic amine radical of the group
consisting of heterocyclic, ureido and hydrazino radicals and the
radical --N(R.sub.3).sub.2 wherein R.sub.3 represents hydrogen or
an alkyl radical containing less than 4 carbon atoms.
[0012] Optically pure forms of halogen substituted
2-phenyl-1,2-ethanediol monocarbamates and dicarbamates have also
been described in U.S. Pat. No. 6,103,759 to Choi, et al (hereby
incorporated by reference), as effective for treating and
preventing central nervous system disorders including convulsions,
epilepsy, stroke and muscle spasm; and as useful in the treatment
of central nervous system diseases, particularly as
anticonvulsants, antiepileptics, neuroprotective agents and
centrally acting muscle relaxants, of the formulae: 5
[0013] wherein one enantiomer predominates and wherein the phenyl
ring is substituted at X with one to five halogen atoms selected
from fluorine, chlorine, bromine or iodine atoms and R.sub.1,
R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each selected
from hydrogen and straight or branched alkyl groups with one to
four carbons optionally substituted with a phenyl group with
substituents selected from the group consisting of hydrogen,
halogen, alkyl, alkyloxy, amino, nitro and cyano. Pure enantiomeric
forms and enantiomeric mixtures were described wherein one of the
enantiomers predominates in the mixture for the compounds
represented by the formulae above; preferably one of the
enantiomers predominates to the extent of about 90% or greater;
and, most preferably, about 98% or greater.
[0014] A halogen substituted 2-phenyl-1,2-ethanediol dicarbamate
compound of Formula (I) has not been previously described as useful
for preventing or treating neuropathic pain or cluster and migraine
headache-associated pain. 6
[0015] Recent preclinical studies have revealed previously
unrecognized pharmacological properties which suggest that a
dicarbamate compound of Formula (I) is useful in preventing or
treating neuropathic pain and cluster and migraine
headache-associated pain. Therefore, it is an object of the present
invention to teach a method for use of a dicarbamate compound of
Formula (I) in preventing or treating neuropathic pain and cluster
and migraine headache-associated pain.
SUMMARY OF THE INVENTION
[0016] The present invention is directed to a method for preventing
or treating neuropathic pain and cluster and migraine
headache-associated pain comprising administering to a subject in
need thereof a therapeutically effective amount of a compound of
Formula (I): 7
Formula (I)
[0017] wherein
[0018] phenyl is substituted at X with one to five halogen atoms
independently selected from the group consisting of fluorine,
chlorine, bromine and iodine; and,
[0019] R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently
selected from the group consisting of hydrogen and C.sub.1-C.sub.4
alkyl; wherein C.sub.1-C.sub.4 alkyl is optionally substituted with
phenyl (wherein phenyl is optionally substituted with substituents
independently selected from the group consisting of halogen,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, amino, nitro and
cyano).
[0020] Embodiments of the invention include a method for preventing
or treating neuropathic pain; wherein neuropathic pain results from
chronic or debilitating conditions comprising administering to a
subject in need thereof a therapeutically effective amount of a
pharmaceutical composition comprising a pharmaceutically acceptable
carrier and a compound of Formula (I).
[0021] Embodiments of the invention include a method for preventing
or treating cluster and migraine headache-associated pain
comprising administering to a subject in need thereof a
therapeutically effective amount of a pharmaceutical composition
comprising a pharmaceutically acceptable carrier and a compound of
Formula (I).
[0022] Embodiments of the method include the use of a compound of
Formula (I) for the preparation of a medicament for preventing or
treating neuropathic pain and cluster and migraine
headache-associated pain in a subject in need thereof.
[0023] Embodiments of the method include the use of a racemic
mixture of a compound of Formula (I), an enantiomer of Formula (I)
or an enantiomeric mixture wherein an enantiomer of Formula (I)
predominates. For an enantiomeric mixture wherein an enantiomer of
Formula (I) predominates, preferably, an enantiomer of Formula (I)
predominates to the extent of about 90% or greater. More
preferably, an enantiomer of Formula (I) predominates to the extent
of about 98% or greater.
DETAILED DESCRIPTION OF THE INVENTION
[0024] The present invention is directed to a method for preventing
or treating neuropathic pain and cluster and migraine
headache-associated pain comprising administering to a subject in
need thereof a therapeutically effective amount of a compound of
Formula (I): 8
[0025] wherein
[0026] phenyl is substituted at X with one to five halogen atoms
independently selected from the group consisting of fluorine,
chlorine, bromine and iodine; and,
[0027] R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently
selected from the group consisting of hydrogen and C.sub.1-C.sub.4
alkyl; wherein C.sub.1-C.sub.4 alkyl is optionally substituted with
phenyl (wherein phenyl is optionally substituted with substituents
independently selected from the group consisting of halogen,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, amino, nitro and
cyano).
[0028] The present method includes the use of a compound of Formula
(I) wherein X is chlorine; preferably, X is substituted at the
ortho position of the phenyl ring.
[0029] The present method also includes the use of a compound of
Formula (I) wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are
preferably selected from hydrogen.
[0030] An embodiment of the present method includes the use of a
racemic mixture of a compound of Formula (I), an enantiomer of
Formula (I) or an enantiomeric mixture wherein an enantiomer of
Formula (I) predominates wherein X is chlorine; preferably, X is
substituted at the ortho position of the phenyl ring.
[0031] The present method also includes the use of a racemic
mixture of a compound of Formula (I), an enantiomer of Formula (I)
or an enantiomeric mixture wherein an enantiomer of Formula (I)
predominates wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are
preferably selected from hydrogen.
[0032] For an enantiomeric mixture wherein an enantiomer of Formula
(I) predominates, preferably, an enantiomer of Formula (I)
predominates to the extent of about 90% or greater. More
preferably, an enantiomer of Formula (I) predominates to the extent
of about 98% or greater.
[0033] An embodiment of the present method includes a method for
preventing or treating neuropathic pain and cluster and migraine
headache-associated pain comprising administering to a subject in
need thereof a therapeutically effective amount of a compound of
Formula (Ia): 9
[0034] wherein
[0035] R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently
selected from the group consisting of hydrogen and C.sub.1-C.sub.4
alkyl; wherein C.sub.1-C.sub.4 alkyl is optionally substituted with
phenyl (wherein phenyl is optionally substituted with substituents
independently selected from the group consisting of halogen,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, amino, nitro and
cyano).
[0036] The present method includes the use of a compound of Formula
(Ia) wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are preferably
selected from hydrogen.
[0037] An embodiment of the present method includes the use of a
racemic mixture of a compound of Formula (Ia), an enantiomer of
Formula (Ia) or an enantiomeric mixture wherein an enantiomer of
Formula (Ia) predominates wherein X is chlorine; preferably, X is
substituted at the ortho position of the phenyl ring.
[0038] The present method also includes the use of a racemic
mixture of a compound of Formula (Ia), an enantiomer of Formula
(Ia) or an enantiomeric mixture wherein an enantiomer of Formula
(Ia) predominates wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are
preferably selected from hydrogen.
[0039] For an enantiomeric mixture wherein an enantiomer of Formula
(Ia) predominates, preferably, an enantiomer of Formula (Ia)
predominates to the extent of about 90% or greater. More
preferably, an enantiomer of Formula (Ia) predominates to the
extent of about 98% or greater.
[0040] An embodiment of the present method includes a method for
preventing or treating neuropathic pain and cluster and migraine
headache-associated pain comprising administering to a subject in
need thereof a therapeutically effective amount of a compound of
Formula (Ib): 10
[0041] An embodiment of the present method includes the use of a
racemic mixture of a compound of Formula (Ib), an enantiomer of
Formula (Ib) or an enantiomeric mixture wherein an enantiomer of
Formula (Ib) predominates.
[0042] For an enantiomeric mixture wherein an enantiomer of Formula
(Ib) predominates, preferably, an enantiomer of Formula (Ib)
predominates to the extent of about 90% or greater. More
preferably, an enantiomer of Formula (Ib) predominates to the
extent of about 98% or greater.
[0043] An embodiment of the present method includes a method for
preventing or treating neuropathic pain and cluster and migraine
headache-associated pain comprising administering to a subject in
need thereof a therapeutically effective amount of an enantiomer of
Formula (Ic) or an enantiomeric mixture wherein the enantiomer of
Formula (Ic) predominates: 11
[0044] For an enantiomeric mixture wherein the enantiomer of
Formula (Ic) predominates, preferably, the enantiomer of Formula
(Ic) predominates to the extent of about 90% or greater. More
preferably, the enantiomer of Formula (Ic) predominates to the
extent of about 98% or greater.
[0045] Other crystal forms of an enantiomer of Formula (I) may
exist and as such are intended to be included in the present
invention.
[0046] It is apparent to those skilled in the art that the
compounds of the invention are present as a racemic mixture,
enantiomers and enantiomeric mixtures thereof. A carbamate compound
selected from the group consisting of Formula (I), Formula (Ia),
Formula (Ib) and Formula (Ic) contains an asymmetric chiral carbon
atom at the benzylic position, which is the aliphatic carbon
adjacent to the phenyl ring (represented by the asterisk in the
structural formulae).
[0047] Compounds of the present invention may be prepared as
described in the previously referenced Bossinger '728 patent
(incorporated by reference), Bossinger '692 patent (incorporated by
reference) and Choi '759 patent (incorporated by reference).
[0048] It is intended that the definition of any substituent or
variable at a particular location in a molecule be independent of
its definitions elsewhere in that molecule. It is understood that
substituents and substitution patterns on the compounds of this
invention can be selected by one of ordinary skill in the art to
provide compounds that are chemically stable and that can be
readily synthesized by techniques known in the art as well as those
methods set forth herein.
[0049] The present invention contemplates a method for preventing
or treating neuropathic pain and cluster and migraine
headache-associated pain in a subject in need thereof comprising
administering to the subject a therapeutically effective amount of
a compound of Formula (I).
[0050] An embodiment of the present invention includes a method for
preventing or treating neuropathic pain resulting from chronic or
debilitating conditions in a subject in need thereof. The chronic
or debilitating conditions that lead to neuropathic pain include,
but are not limited to, painful diabetic peripheral neuropathy,
post-herpetic neuralgia, trigeminal neuralgia, post-stroke pain,
multiple sclerosis-associated pain, neuropathies-associated pain
such as in idiopathic or post-traumatic neuropathy and
mononeuritis, HIV-associated neuropathic pain, cancer-associated
neuropathic pain, carpal tunnel-associated neuropathic pain, spinal
cord injury-associated pain, complex regional pain syndrome,
fibromyalgia-associated neuropathic pain, lumbar and cervical pain,
reflex sympathic dystrophy, phantom limb syndrome and other chronic
and debilitating condition-associated pain syndromes.
[0051] An embodiment of the present invention also includes a
method for preventing or treating cluster and migraine
headache-associated pain in a subject in need thereof. Cluster
headache-associated pain is characterized by a series of
short-lived attacks on an almost daily basis over a relatively
short period of time followed by a pain-free interval. Migraine
headache-associated pain is characterized by blinding pain,
vomiting, photophobia and recurrence at regular interval; and,
includes, but is not limited to, classic migraine
headache-associated pain (migraine with aura) and common migraine
headache-associated pain (migraine without aura).
[0052] An embodiment of the invention also includes a method for
slowing or delaying the progression of neuropathic pain and cluster
and migraine headache-associated pain in a subject in need thereof
comprising administering to the subject a therapeutically effective
amount of a compound of Formula (I).
[0053] The term "slowing or delaying the progression of"
neuropathic pain and cluster and migraine headache-associated pain
is intended to include minimizing the severity, duration and
frequency of the clinical manifestations associated with
neuropathic pain and cluster and migraine headache-associated pain
in a subject.
[0054] An example of the method of the present invention comprises
administering to the subject a therapeutically effective amount of
a compound of Formula (I) in a pharmaceutical composition
comprising a pharmaceutically acceptable carrier and a compound of
Formula (I). The method of the present invention also includes the
use of a compound of Formula (I) for the preparation of a
medicament for preventing or treating neuropathic pain and cluster
and migraine headache-associated pain.
[0055] Another example of the method of the present invention
comprises administering to the subject a therapeutically effective
amount of a compound of Formula (I) or pharmaceutical composition
thereof in combination with one or more agents useful in preventing
or treating neuropathic pain and cluster and migraine
headache-associated pain.
[0056] A compound of Formula (I) or pharmaceutical composition
thereof may be administered by any conventional route of
administration including, but not limited to oral, pulmonary,
intraperitoneal (ip), intravenous (iv), intramuscular (im),
subcutaneous (sc), transdermal, buccal, nasal, sublingual, ocular,
rectal and vaginal. In addition, administration directly to the
nervous system may include, and are not limited to, intracerebral,
intraventricular, intracerebroventricular, intrathecal,
intracisternal, intraspinal or peri-spinal routes of administration
by delivery via intracranial or intravertebral needles or catheters
with or without pump devices. It will be readily apparent to those
skilled in the art that any dose or frequency of administration
that provides the therapeutic effect described herein is suitable
for use in the present invention.
[0057] The therapeutically effective amount of a compound of
Formula (I) or pharmaceutical composition thereof may be from about
0.01 mg/Kg/dose to about 100 mg/Kg/dose. Preferably, the
therapeutically effective amount may be from about 0.01 mg/Kg/dose
to about 25 mg/Kg/dose. More preferably, the therapeutically
effective amount may be from about 0.01 mg/Kg/dose to about 10
mg/Kg/dose. Most preferably, the therapeutically effective amount
may be from about 0.01 mg/Kg/dose to about 5 mg/Kg/dose. Therefore,
the therapeutically effective amount of the active ingredient
contained per dosage unit (e.g., tablet, capsule, powder,
injection, suppository, teaspoonful and the like) as described
herein may be from about 1 mg/day to about 7000 mg/day for a
subject, for example, having an average weight of 70 Kg.
[0058] The dosages, however, may be varied depending upon the
requirement of the subjects (including factors associated with the
particular subject being treated, including subject age, weight and
diet, strength of the preparation, the advancement of the disease
condition and the mode and time of administration).
[0059] Optimal dosages to be administered may be readily determined
by those skilled in the art and will result in the need to adjust
the dose to an appropriate therapeutic level. The use of either
daily administration or post-periodic dosing may be employed.
Preferably, a compound of Formula (I) or pharmaceutical composition
thereof is administered orally or parenterally. More preferably, a
compound of Formula (I) or pharmaceutical composition thereof is
administered orally.
[0060] In accordance with the methods of the present invention, a
compound of Formula (I) or pharmaceutical composition thereof
described herein may be administered separately, at different times
during the course of therapy or concurrently in divided combination
or single combination forms. Advantageously, a compound of Formula
(I) or pharmaceutical composition thereof may be administered in a
single daily dose or the total daily dosage may be administered via
continuous delivery or in divided doses of two, three or four times
daily. The instant invention is therefore to be understood as
embracing all such methods and regimes of simultaneous or
alternating treatment and the term "administering" is to be
interpreted accordingly.
[0061] The term "subject" as used herein, refers to an animal,
preferably a mammal, most preferably a human, who has been the
object of treatment, observation or experiment.
[0062] The term "therapeutically effective amount" as used herein,
means that amount of active compound or pharmaceutical agent that
elicits the biological or medicinal response in a tissue system
(preferably, an animal; more preferably, a mammal; most preferably,
a human) that is being sought by a researcher, veterinarian,
medical doctor, or other clinician, which includes alleviation of
the symptoms of the disease or disorder being treated.
[0063] As used herein, the term "composition" is intended to
encompass a product comprising the specified ingredients in the
specified amounts, as well as any product which results, directly
or indirectly, from combinations of the specified ingredients in
the specified amounts.
[0064] To prepare a pharmaceutical composition of the present
invention, a compound of Formula (I) as the active ingredient is
intimately admixed with a pharmaceutical carrier according to
conventional pharmaceutical compounding techniques, which carrier
may take a wide variety of forms depending of the form of
preparation desired for administration (e.g. oral or parenteral).
Suitable pharmaceutically acceptable carriers are well known in the
art. Descriptions of some of these pharmaceutically acceptable
carriers may be found in The Handbook of Pharmaceutical Excipients,
published by the American Pharmaceutical Association and the
Pharmaceutical Society of Great Britain.
[0065] Methods of formulating pharmaceutical compositions have been
described in numerous publications such as Pharmaceutical Dosage
Forms: Tablets, Second Edition, Revised and Expanded, Volumes 1-3,
edited by Lieberman et al; Pharmaceutical Dosage Forms: Parenteral
Medications, Volumes 1-2, edited by Avis et al; and Pharmaceutical
Dosage Forms: Disperse Systems, Volumes 1-2, edited by Lieberman et
al; published by Marcel Dekker, Inc.
[0066] Preferably a pharmaceutical composition is in a unit dosage
form such as a tablet, pill, capsule, caplet, gelcap, lozenge,
granule, powder, sterile parenteral solution or suspension, metered
aerosol or liquid spray, drop, ampoule, autoinjector device or
suppository for administration by oral, intranasal, sublingual,
intraocular, transdermal, parenteral, rectal, vaginal, inhalation
or insufflation means. Alternatively, the composition may be
presented in a form suitable for once-weekly or once-monthly
administration or may be adapted to provide a preparation for
intramuscular injection.
[0067] In preparing a pharmaceutical composition having a solid
dosage form for oral administration, such as a tablet, pill,
capsule, caplet, gelcap, lozenge, granule or powder (each including
immediate release, timed release and sustained release
formulations), suitable carriers and additives include but are not
limited to diluents, granulating agents, lubricants, binders,
glidants, disintegrating agents and the like. If desired, tablets
may be sugar coated, gelatin coated, film coated or enteric coated
by standard techniques.
[0068] For preparing a solid dosage form, the principal active
ingredient is mixed with a pharmaceutical carrier (e.g.
conventional tableting ingredients such as diluents, binders,
adhesives, disintegrants, lubricants, antiadherents and glidants).
Sweeteners and flavorants may be added to chewable solid dosage
forms to improve the palatability of the oral dosage form.
Additionally, colorants and coatings may be added or applied to the
solid dosage form for ease of identification of the drug or for
aesthetic purposes. These carriers are formulated with the
pharmaceutical active to provide an accurate, appropriate dose of
the pharmaceutical active with a therapeutic release profile.
[0069] In preparing a pharmaceutical composition having a liquid
dosage form for oral, topical and parenteral administration, any of
the usual pharmaceutical media or excipients may be employed. Thus,
for liquid unit dosage forms, such as suspensions (i.e. colloids,
emulsions and dispersions) and solutions, suitable carriers and
additives include but are not limited to pharmaceutically
acceptable wetting agents, dispersants, flocculation agents,
thickeners, pH control agents (i.e. buffers), osmotic agents,
coloring agents, flavors, fragrances, preservatives (i.e. to
control microbial growth, etc.) and a liquid vehicle may be
employed. Not all of the components listed above will be required
for each liquid dosage form. The liquid forms in which the novel
compositions of the present invention may be incorporated for
administration orally or by injection include, but are not limited
to aqueous solutions, suitably flavored syrups, aqueous or oil
suspensions, and flavored emulsions with edible oils such as
cottonseed oil, sesame oil, coconut oil or peanut oil, as well as
elixirs and similar pharmaceutical vehicles.
BIOLOGICAL EXPERIMENTAL EXAMPLES
[0070] The activity of a compound Formula (I) for use in the
treatment of neuropathic pain was evaluated in the following
experimental examples and is intended to be a way of illustrating
but not limiting the invention.
[0071] The procedure used to test the antiallodynic activity of a
compound of Formula (I) was the procedure for the measurement of
allodynia found in the Chung Model (Kim S. H. and Chung J. M., An
Experimental Model for Peripheral Neuropathy Produced by Segmental
Spinal Nerve Ligation in the Rat, Pain, 1992, 50, 355-363).
Example 1
[0072] Evaluation of Antiallodynic Activity (Manually Applied Von
Frey Probes) Animals
[0073] Pathogen-free, male albino Sprague-Dawley rats, 200 g, were
purchased from Harlan Industries (Indianapolis, Ind.) and
maintained on a 12-h light/dark cycle (lights on at 06:00 h) in a
climate-controlled room with food and water available ad libitum up
to the time of the testing and food withdrawn 18 hr prior to
testing.
[0074] Surgical Procedure and Measurement of Allodynia
[0075] The rats were anesthetized with isoflurane inhalant
anesthesia. The left lumbar spinal nerve at the level of L5 was
tightly ligated (4-0 silk suture) distal to the dorsal root
ganglion and prior to entrance into the sciatic nerve, as described
by Kim and Chung. The incisions were closed and the rats were
allowed to recover under conditions described above. This procedure
results in mechanical allodynia in the left hind paw. The sham
operation, when performed, consisted of a similar surgical
procedure lacking only the final ligation of the spinal nerve.
Mechanical (tactile) allodynia was assessed by recording the
pressure at which the affected paw (ipsilateral to the site of
nerve injury) was withdrawn from graded stimuli (von Frey filaments
ranging from 4.0 to 148.1 mN) applied by hand perpendicularly to
the plantar surface of the paw (between the footpads) through
wire-mesh observation cages. A paw withdrawal threshold (PWT) was
determined by sequentially increasing and decreasing the stimulus
strength and analyzing withdrawal data using a Dixon non-parametric
test, as described by Chaplan et al (Chaplan S. R., Bach F. W.,
Pogrel J. W., Chung J. M. and Yaksh T. L., Quantitative Assessment
of Tactile Allodynia in the Rat Paw, J Neurosci Meth, 1994, 53,
55-63). Normal rats, sham operated rats, and the contralateral paw
of L5 ligated rats withstand at least 148.1 mN (equivalent to 15 g)
of pressure without responding. Spinal nerve ligated rats respond
to as little as 4.0 mN (equivalent to 0.41 g) of pressure on the
affected paw. Rats were included in the study only if they did not
exhibit motor dysfunction (e.g., paw dragging or dropping) and
their PWT was below 39.2 mN (equivalent to 4.0 g). The PWT was used
to calculate the % maximal possible effect (% MPE) according to the
formula:
% MPE=100.times.(PWT-CT)/(CO-CT).
[0076] Data Analysis
[0077] As summarized in Table 1 below, the enantiomer of Formula
(Ic) was screened for antiallodynic activity in the Chung model of
neuropathic pain at a dose of 30 and 100 mg/Kg, po, with responses
being measured at 0.5, 1, 2 and 4 hours post dosing; responses
returned to baseline by one hour. Data for 30 mg/Kg is at the time
of peak effect, 30 minutes after oral dosing, with n=5 animals per
dose. Data for 100 mg/Kg is at the time of peak effect, 30 to 60
minutes after oral dosing, with n=10 animals per dose.
1TABLE 1 Antiallodynic Effect Assessed with Manually Applied Von
Frey Probes Dose % Maximum (mg/Kg) Possible Effect n 30 0 5 100
25.7 10
[0078] Example 2
[0079] Evaluation of Antiallodynic Activity (Electronic Von Frey
Probes) Animals
[0080] Pathogen-free, male Rj: Wistar (Han) rats (300-380 g) were
purchased from Elevage Janvier, 53940 Le Genest-Saint-Isle, France.
The animals were maintained on a 12-h light/dark cycle (lights on
from 7:00-19:00) in a controlled ambient temperature of
21.+-.1.degree. C., and relative humidity maintained at 40-70%. The
animals had free access to food (UAR 113) and tap water until
tested.
[0081] Surgical Procedure
[0082] Rats were anesthetized (sodium pentobarbital 40 mg/kg i.p.).
A ligature was tied tightly around the left L5 and L6 spinal
nerves. The rats received an i.m. injection of 50000 IU Penicillin
(Diamant.RTM.) and were allowed to recover. This procedure results
in mechanical allodynia in the left hind paw. Two weeks after the
surgery, when the allodynic state was fully developed, rats were
submitted consecutively to tactile stimulation of both the
non-lesioned and the lesioned hindpaws.
[0083] Measurement of Allodynia
[0084] The animals were placed on an elevated grid floor in
Plexiglass boxes (19.times.11.5.times.13 cm). The tip of an
electronic Von Frey probe (Bioseb, Model 1610) was then applied
with increasing pressure to the lesioned and non-lesioned hindpaws
and the force required to induce paw-withdrawal was automatically
recorded. Prior to receiving drug treatment all animals were
submitted to tactile stimulation and assigned to treatment groups
matched on the basis of their pain response. This procedure was
carried out 3 times for each paw and the mean paw force was
calculated to provide basic scores per animal. Data were expressed
as percent change (means.+-.SEM) of effectiveness from the
controls. Statistical analysis was done using non-paired and paired
Student's t tests.
[0085] Drug Administration and Testing Schedule
[0086] As summarized in Table 2 below, the enantiomer of Formula
(Ic) was evaluated at the doses 10, 30 and 100 mg/kg (n=8),
administered p.o. in a volume of 5 mL/kg. Morphine (128 mg/kg) was
used as reference substance. Control animals received a p.o.
administration of vehicle. The test was performed blind 30, 60 and
90 minutes after drug administration.
[0087] Data Analysis
[0088] The enantiomer of Formula (Ic) non-dose-dependently
increased the force required to induce paw-withdrawal in the
ligatured paw in response to tactile stimulation at the 60 minute
post-dosing measurement without affecting the non-ligatured paw.
These effects were significant at all three doses (10, 30 and 100
mg/Kg) tested and appeared more marked than that observed with the
morphine positive control (38% change at 128 mg/Kg morphine). This
significant anti-allodynic effect of the enantiomer of Formula (Ic)
was no longer present by 90 minutes post-dosing (ns: p value is not
significant).
2TABLE 2 Antiallodynic Activity Electronic Von Frey Probes Dose %
(mg/Kg) Change n p 0 0 8 -- 10 69 8 <0.05 30 115 8 <0.01 100
88 8 <0.01
* * * * *